hansoh glp 1 Merck strikes a $2B GLP-1 deal with Hansoh Pharma licenses dual incretin
Description
Retrieved from Marso, S
Adherence to Therapy: Only 32% of GLP-1 users remained on therapy at the end of year one, dropping to 15% by year two
In addition to achieving significant weight loss, research has shown that GLP-1 drugs can reduce the risk of major cardiovascular events such as heart attack or stroke in people with Type 2 diabetes
However, they remain useful for mechanistic insights, such as exploring AD molecular signaling and its connection with antidiabetic drugs
Accessed June 10, 2024
Author Contributions Concept and design: Jos Emiliano Gonzlez Flores, Luis M
